<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03449082</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-RM-SGChung-ASC-02</org_study_id>
    <nct_id>NCT03449082</nct_id>
  </id_info>
  <brief_title>Treatment of Intractable Common Extensor Tendon Injury Using Mesenchymal Stem Cells (Allo-ASC)</brief_title>
  <official_title>Treatment of Intractable Common Extensor Tendon Injury Using Allogeneic Adipose-derived Mesenchymal Stem Cells (Allo-ASC): a Phase II Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea Health Industry Development Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy and safety of intra-tendon injection of
      allogeneic adipose-derived mesenchymal stem cells (Allo-ASC) in intractable common extensor
      tendinosis patients in comparison with a control treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase II randomized placebo controlled trial will be done with following 3 groups. Each
      group will have 10 participants, so, the total patients will be 30 people.

        1. High concentration of Allo-ASC group: stem cell 0.5cc (Total: 10 million cells) + Fibrin
           glue 0.5cc

        2. Low concentration of Allo-ASC group: stem cell 0.5cc (Total: 1 million cells) + Fibrin
           glue 0.5cc

        3. Placebo Comparator (Fibrin) group: Normal saline 0.5cc + Fibrin glue 0.5cc The
           investigators will compare the efficacy difference with visual analogue scale (VAS)
           during activity (primary outcome), VAS at rest, Mayo elbow performance index (MEPI),
           grip strength, ultrasonographic assessment at baseline, 6 weeks, 12 weeks, 6 months, 12
           months and 24 months after injection. Shear wave elastography (SWE) and magnetic
           resonance image (MRI) will be done at baseline, 12 weeks, 12 months and 24 months after
           injection
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 10, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of pain visual analogue scale (VAS) during activity</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Self reported pain intensity during activity will be evaluated by visual analogue scale (0 = no pain, 10 = pain as bad as can be).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of pain visual analogue scale (VAS) during activity</measure>
    <time_frame>baseline, 6 weeks, 12 weeks, 6 months, 12 months and 24 months</time_frame>
    <description>Self reported pain intensity during activity will be evaluated by visual analogue scale (0 = no pain, 10 = pain as bad as can be).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of pain visual analogue scale (VAS) at rest</measure>
    <time_frame>baseline, 6 weeks, 12 weeks, 6 months, 12 months and 24 months</time_frame>
    <description>Self reported pain intensity at rest will be evaluated by visual analogue scale (0 = no pain, 10 = pain as bad as can be).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Mayo elbow performance index (MEPI)</measure>
    <time_frame>baseline, 6 weeks, 12 weeks, 6 months, 12 months and 24 months</time_frame>
    <description>The MEPI measures pain, motion, stability, and daily functions. (0 = worst, 100 = best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasonographic assessment</measure>
    <time_frame>baseline, 6 weeks, 12 weeks, 6 months, 12 months and 24 months</time_frame>
    <description>Ultrasonographic findings will be analyzed using a 5-point Likert scale (1: more aggravated, 2: aggravated, 3: same, 4: improved, 5: more improved). Sonographic images will be compared with baseline images by experienced ultrasound examiners being blind to the treatment group and the time points of image achievement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shear wave elastography</measure>
    <time_frame>baseline, 12 weeks and 24 months</time_frame>
    <description>Young modulus and shear wave speed will be obtained</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic resonance image (MRI) assessment</measure>
    <time_frame>baseline, 12 weeks and 24 months</time_frame>
    <description>MRI findings will be analyzed using a 5-point Likert scale (1: more aggravated, 2: aggravated, 3: same, 4: improved, 5: more improved). MR images will be compared with baseline images by experienced ultrasound examiners being blind to the treatment group and the time points of image achievement.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lateral Epicondylitis</condition>
  <arm_group>
    <arm_group_label>High concentration of Allo-ASC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High concentration of Allo-ASC 0.5cc (Total: 10 million cells) &amp; Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low concentration of Allo-ASC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low concentration of Allo-ASC 0.5cc (Total: 1 million cells) &amp; Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator (Fibrin) group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline 0.5cc &amp; Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High concentration of Allo-ASC</intervention_name>
    <description>10 million cells of Allo-ASC 0.5cc</description>
    <arm_group_label>High concentration of Allo-ASC group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low concentration of Allo-ASC</intervention_name>
    <description>1 million cells of Allo-ASC 0.5cc</description>
    <arm_group_label>Low concentration of Allo-ASC group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fibrin glue</intervention_name>
    <description>Fibrin glue 0.5cc</description>
    <arm_group_label>High concentration of Allo-ASC group</arm_group_label>
    <arm_group_label>Low concentration of Allo-ASC group</arm_group_label>
    <arm_group_label>Placebo Comparator (Fibrin) group</arm_group_label>
    <other_name>Fibrin sealant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline 0.5cc</description>
    <arm_group_label>Placebo Comparator (Fibrin) group</arm_group_label>
    <other_name>0.9% Sodium Chloride Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinically diagnosed as lateral epicondylosis (tennis elbow)

          -  symptom duration is over 12 months

          -  pain visual analogue scale (VAS) during activity ≥ 5

          -  recurrent pain in spite of conservative treatment such as physical therapy,
             medication, steroid injection

          -  common extensor tendon injury can be observed under ultrasound (hypoechoic lesion) and
             MRI (hyperintensity or discontinuity)

          -  patient that can understand the clinical trials

        Exclusion Criteria:

          -  patient that underwent other injection such as steroid injection or prolotherapy
             within 6 weeks

          -  patients with following conditions (such as arthritis related to the target lesion,
             synovitis related to the target lesion, paralysis related to the target lesion,
             entrapment of related nerve to the target lesion, radiculopathy related to the target
             lesion, infectious disease, generalized pain syndrome, rheumatoid arthritis, impaired
             sensibility, dementia, history of allergic or hypersensitive reaction to
             bovine-derived proteins or Fibrin Glue, contraindication to MRI)

          -  patient that enrolled other clinical trials within 30 days

          -  current pregnancy or breast-feeding, planning for pregnancy

          -  history of drug/alcohol addiction, habitual smoker

          -  operation history of affected elbow

          -  previous clinical trial involving stem cell administration

          -  other severe medical illness or bleeding tendency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun Gun Chung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sun Gun Chung, MD, PhD</last_name>
    <phone>+82-2-2072-2560</phone>
    <email>suncg@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jae Hyeon Park, MD</last_name>
    <phone>+82-2-2072-3401</phone>
    <email>cupiote@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun Gun Chung, MD, PhD</last_name>
      <phone>+82-2-2072-3954</phone>
      <email>suncg@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Lee SY, Kim W, Lim C, Chung SG. Treatment of Lateral Epicondylosis by Using Allogeneic Adipose-Derived Mesenchymal Stem Cells: A Pilot Study. Stem Cells. 2015 Oct;33(10):2995-3005. doi: 10.1002/stem.2110. Epub 2015 Aug 6.</citation>
    <PMID>26202898</PMID>
  </reference>
  <reference>
    <citation>Lee SY, Kwon B, Lee K, Son YH, Chung SG. Therapeutic Mechanisms of Human Adipose-Derived Mesenchymal Stem Cells in a Rat Tendon Injury Model. Am J Sports Med. 2017 May;45(6):1429-1439. doi: 10.1177/0363546517689874. Epub 2017 Mar 14.</citation>
    <PMID>28291954</PMID>
  </reference>
  <reference>
    <citation>Pascual-Garrido C, Rolón A, Makino A. Treatment of chronic patellar tendinopathy with autologous bone marrow stem cells: a 5-year-followup. Stem Cells Int. 2012;2012:953510. doi: 10.1155/2012/953510. Epub 2011 Dec 18.</citation>
    <PMID>22220180</PMID>
  </reference>
  <reference>
    <citation>Ellera Gomes JL, da Silva RC, Silla LM, Abreu MR, Pellanda R. Conventional rotator cuff repair complemented by the aid of mononuclear autologous stem cells. Knee Surg Sports Traumatol Arthrosc. 2012 Feb;20(2):373-7. doi: 10.1007/s00167-011-1607-9. Epub 2011 Jul 20.</citation>
    <PMID>21773831</PMID>
  </reference>
  <reference>
    <citation>Hernigou P, Flouzat Lachaniette CH, Delambre J, Zilber S, Duffiet P, Chevallier N, Rouard H. Biologic augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: a case-controlled study. Int Orthop. 2014 Sep;38(9):1811-8. doi: 10.1007/s00264-014-2391-1. Epub 2014 Jun 7.</citation>
    <PMID>24913770</PMID>
  </reference>
  <reference>
    <citation>Zhang X, Lin YC, Rui YF, Xu HL, Chen H, Wang C, Teng GJ. Therapeutic Roles of Tendon Stem/Progenitor Cells in Tendinopathy. Stem Cells Int. 2016;2016:4076578. doi: 10.1155/2016/4076578. Epub 2016 Apr 19. Review.</citation>
    <PMID>27195010</PMID>
  </reference>
  <reference>
    <citation>Clarke AW, Alyas F, Morris T, Robertson CJ, Bell J, Connell DA. Skin-derived tenocyte-like cells for the treatment of patellar tendinopathy. Am J Sports Med. 2011 Mar;39(3):614-23. doi: 10.1177/0363546510387095. Epub 2010 Dec 7.</citation>
    <PMID>21139155</PMID>
  </reference>
  <reference>
    <citation>Leong DJ, Sun HB. Mesenchymal stem cells in tendon repair and regeneration: basic understanding and translational challenges. Ann N Y Acad Sci. 2016 Nov;1383(1):88-96. doi: 10.1111/nyas.13262. Epub 2016 Oct 5. Review.</citation>
    <PMID>27706825</PMID>
  </reference>
  <reference>
    <citation>Müller SA, Todorov A, Heisterbach PE, Martin I, Majewski M. Tendon healing: an overview of physiology, biology, and pathology of tendon healing and systematic review of state of the art in tendon bioengineering. Knee Surg Sports Traumatol Arthrosc. 2015 Jul;23(7):2097-105. doi: 10.1007/s00167-013-2680-z. Epub 2013 Sep 21. Review.</citation>
    <PMID>24057354</PMID>
  </reference>
  <reference>
    <citation>Coombes BK, Bisset L, Vicenzino B. Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. Lancet. 2010 Nov 20;376(9754):1751-67. doi: 10.1016/S0140-6736(10)61160-9. Epub 2010 Oct 21. Review.</citation>
    <PMID>20970844</PMID>
  </reference>
  <reference>
    <citation>Maffulli N, Longo UG, Denaro V. Novel approaches for the management of tendinopathy. J Bone Joint Surg Am. 2010 Nov 3;92(15):2604-13. doi: 10.2106/JBJS.I.01744. Review.</citation>
    <PMID>21048180</PMID>
  </reference>
  <reference>
    <citation>Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. Am J Sports Med. 2010 Feb;38(2):255-62. doi: 10.1177/0363546509355445.</citation>
    <PMID>20448192</PMID>
  </reference>
  <reference>
    <citation>Tobita M, Orbay H, Mizuno H. Adipose-derived stem cells: current findings and future perspectives. Discov Med. 2011 Feb;11(57):160-70. Review.</citation>
    <PMID>21356171</PMID>
  </reference>
  <reference>
    <citation>Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med. 2006 Nov;34(11):1774-8. Epub 2006 May 30.</citation>
    <PMID>16735582</PMID>
  </reference>
  <reference>
    <citation>Chong AK, Ang AD, Goh JC, Hui JH, Lim AY, Lee EH, Lim BH. Bone marrow-derived mesenchymal stem cells influence early tendon-healing in a rabbit achilles tendon model. J Bone Joint Surg Am. 2007 Jan;89(1):74-81.</citation>
    <PMID>17200313</PMID>
  </reference>
  <reference>
    <citation>Nixon AJ, Dahlgren LA, Haupt JL, Yeager AE, Ward DL. Effect of adipose-derived nucleated cell fractions on tendon repair in horses with collagenase-induced tendinitis. Am J Vet Res. 2008 Jul;69(7):928-37. doi: 10.2460/ajvr.69.7.928.</citation>
    <PMID>18593247</PMID>
  </reference>
  <reference>
    <citation>Guadalajara H, Herreros D, De-La-Quintana P, Trebol J, Garcia-Arranz M, Garcia-Olmo D. Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. Int J Colorectal Dis. 2012 May;27(5):595-600. doi: 10.1007/s00384-011-1350-1. Epub 2011 Nov 9.</citation>
    <PMID>22065114</PMID>
  </reference>
  <reference>
    <citation>Guest DJ, Smith MR, Allen WR. Monitoring the fate of autologous and allogeneic mesenchymal progenitor cells injected into the superficial digital flexor tendon of horses: preliminary study. Equine Vet J. 2008 Mar;40(2):178-81. doi: 10.2746/042516408X276942.</citation>
    <PMID>18267891</PMID>
  </reference>
  <reference>
    <citation>Hohendorff B, Siepen W, Spiering L, Staub L, Schmuck T, Boss A. Long-term results after operatively treated Achilles tendon rupture: fibrin glue versus suture. J Foot Ankle Surg. 2008 Sep-Oct;47(5):392-9. doi: 10.1053/j.jfas.2008.05.006. Epub 2008 Jul 14.</citation>
    <PMID>18725118</PMID>
  </reference>
  <reference>
    <citation>Smidt N, van der Windt DA, Assendelft WJ, Devillé WL, Korthals-de Bos IB, Bouter LM. Corticosteroid injections, physiotherapy, or a wait-and-see policy for lateral epicondylitis: a randomised controlled trial. Lancet. 2002 Feb 23;359(9307):657-62.</citation>
    <PMID>11879861</PMID>
  </reference>
  <reference>
    <citation>Jindal N, Gaury Y, Banshiwal RC, Lamoria R, Bachhal V. Comparison of short term results of single injection of autologous blood and steroid injection in tennis elbow: a prospective study. J Orthop Surg Res. 2013 Apr 27;8:10. doi: 10.1186/1749-799X-8-10.</citation>
    <PMID>23621906</PMID>
  </reference>
  <reference>
    <citation>Jacobson JA, Chiavaras MM, Lawton JM, Downie B, Yablon CM, Lawton J. Radial collateral ligament of the elbow: sonographic characterization with cadaveric dissection correlation and magnetic resonance arthrography. J Ultrasound Med. 2014 Jun;33(6):1041-8. doi: 10.7863/ultra.33.6.1041.</citation>
    <PMID>24866611</PMID>
  </reference>
  <reference>
    <citation>Scutt N, Rolf CG, Scutt A. Glucocorticoids inhibit tenocyte proliferation and Tendon progenitor cell recruitment. J Orthop Res. 2006 Feb;24(2):173-82.</citation>
    <PMID>16435354</PMID>
  </reference>
  <reference>
    <citation>Dirrichs T, Quack V, Gatz M, Tingart M, Rath B, Betsch M, Kuhl CK, Schrading S. Shear Wave Elastography (SWE) for Monitoring of Treatment of Tendinopathies: A Double-blinded, Longitudinal Clinical Study. Acad Radiol. 2018 Mar;25(3):265-272. doi: 10.1016/j.acra.2017.09.011. Epub 2017 Nov 16.</citation>
    <PMID>29153963</PMID>
  </reference>
  <reference>
    <citation>Domenichini R, Pialat JB, Podda A, Aubry S. Ultrasound elastography in tendon pathology: state of the art. Skeletal Radiol. 2017 Dec;46(12):1643-1655. doi: 10.1007/s00256-017-2726-2. Epub 2017 Aug 1. Review.</citation>
    <PMID>28765991</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Sun Gun Chung</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>adipose derived mesenchymal stem cell</keyword>
  <keyword>allogeneic stem cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tennis Elbow</mesh_term>
    <mesh_term>Tendon Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

